BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Qiu Q, Duan XW, Li Y, Yang LK, Chen Y, Li H, Duan ZP, Wang L. Impact of partial reimbursement on hepatitis B antiviral utilization and adherence. World J Gastroenterol 2015; 21(32): 9588-9597 [PMID: 26327766 DOI: 10.3748/wjg.v21.i32.9588]
URL: https://www.wjgnet.com/1007-9327/full/v21/i32/9588.htm
Number Citing Articles
1
Feng Zhou, Weidong Jia, Shuo Yang, Ge Chen, Guanhai Li, Yueping Li, Yingfang Liang, Yi Yang, Yanhui Gao, Yue Chen. Antiviral drug Utilization and Annual Expenditures for Patients with Chronic HBV Infection in Guangzhou, China, in 2008–2015Antiviral Therapy 2019; 24(6): 405 doi: 10.3851/IMP3326
2
Prowpanga Udompap, Tawesak Tanwandee, Rino Gani. Affordability of Antiviral Therapy in Asia‐Pacific Countries and Its Impact on Public Health OutcomesClinical Liver Disease 2020; 16(6): 249 doi: 10.1002/cld.977
3
Keng Lai, Chi Zhang, Weixia Ke, Yanhui Gao, Shudong Zhou, Li Liu, Yi Yang. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in ChinaClinical Drug Investigation 2017; 37(3): 233 doi: 10.1007/s40261-016-0486-8
4
Nathan Ford, Roz Scourse, Maud Lemoine, Yvan Hutin, Marc Bulterys, Zara Shubber, Dmytro Donchuk, Gilles Wandeler. Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta‐AnalysisHepatology Communications 2018; 2(10): 1160 doi: 10.1002/hep4.1247
5
Hanchao Cheng, Shiyang Liu, Simon Luo, Polin Chan, Zhongdan Chen, Linh‐Vi Le, Jing Sun. Uptake of hepatitis B antiviral treatment: A panel data analysis of 31 provinces in China (2013–2020)Liver International 2022; 42(8): 1762 doi: 10.1111/liv.15321
6
玉娇 常. Progress of Research on the Current Status and Influencing Factors of Medication Adherence in Chronic Hepatitis B PatientsAdvances in Clinical Medicine 2024; 14(05): 787 doi: 10.12677/acm.2024.1451492
7
Li Xie, Juan Yin, Ruyi Xia, Guihua Zhuang. Cost‐effectiveness of antiviral treatment after resection in hepatitis B virus–related hepatocellular carcinoma patients with compensated cirrhosisHepatology 2018; 68(4): 1476 doi: 10.1002/hep.29922
8
Rodrigo M Abreu, Leda C Bassit, Sijia Tao, Yong Jiang, Aline S Ferreira, Patrícia CA Hori, Lilia M Ganova-Raeva, Yury Khudyakov, Raymond F Schinazi, Flair J Carrilho, Suzane K Ono. Long-term Virological and Adherence Outcomes to Antiviral Treatment in a 4-year Cohort Chronic HBV StudyAntiviral Therapy 2019; 24(8): 567 doi: 10.3851/IMP3338
9
Min Li, Lianhui Zhao, Jialing Zhou, Yameng Sun, Xiaoning Wu, Xiaojuan Ou, Hong You, Yuanyuan Kong, Jidong Jia. Changing clinical care cascade of patients with chronic hepatitis B in Beijing, ChinaThe Lancet Regional Health - Western Pacific 2021; 16: 100249 doi: 10.1016/j.lanwpc.2021.100249
10
Xiaodong Guan, Ye Tian, Dennis Ross-Degnan, Chunxia Man, Luwen Shi. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in ChinaBMJ Open 2018; 8(7): e022328 doi: 10.1136/bmjopen-2018-022328
11
Min Li, Yuan Yuan Kong, Shan Shan Wu, Jia Ling Zhou, Xiao Ning Wu, Lin Wang, Jian Ting Su, Xiao Juan Ou, Hong You, Xue Qin Xie, Zai Hua Wei, Ji Dong Jia. Impact of reimbursement program on liver‐related mortality in patients with chronic hepatitis B in Beijing, ChinaJournal of Digestive Diseases 2019; 20(9): 467 doi: 10.1111/1751-2980.12794
12
Shan Shan, Xinyan Zhao, Jidong Jia. Comprehensive approach to controlling chronic hepatitis B in ChinaClinical and Molecular Hepatology 2024; 30(2): 135 doi: 10.3350/cmh.2023.0412